ANVISA-2020-0045-V245

Type II variation for application ANVISA-2020-0045. Type II variation: Analytical Method Change for Immunovant-α — critical change

Variation Number
ANVISA-2020-0045-V245
Type
Type II
Application
ANVISA-2020-0045
Change
CHG-2024-0245
Status
Draft
Fee
€75,521
Submitted
2022-08-18
Approved
—
Description

Type II variation: Analytical Method Change for Immunovant-α — critical change